ArticleIntestinal Failure (New York, N.Y.)
Impact of plasma aluminum on neurocognitive outcomes at early school age in children with intestinal failure.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aluminum (AL) is a known contaminant in parenteral nutrition (PN) and is associated with bone disease, and neurotoxicity. We aimed to evaluate the association between plasma AL concentration and neurocognitive outcomes at early school age, in children with intestinal failure (IF) receiving long-term PN. Methods: This retrospective cohort study included children diagnosed with IF before 2 years of age, with at least one measurement of plasma AL who completed a neuropsychological assessment between 4 and 8 years. Spearman correlation coefficient was used to explore the association between AL concentrations and neurocognitive scores. Results: Nineteen patients (12 males, median gestational age of 35 weeks) were included. The median number of PN years was 9.5 (IQR 7.4-11.8). Median and peak AL concentrations were 363 nmol/L (IQR 233-580) and 832 nmol/L (IQR 491.5-1361.5), respectively. Mean age at assessment was 6.32 + /-0.92 years. The mean full-scale intelligence quotient (FSIQ) was 95.8 + /-13.8. There was a moderate, inverse correlation between mean AL concentration before age three (- 0.56, p = 0.020) and FSIQ. For other domains, the strongest association was found between visual memory and the mean AL concentration before assessment (-0.67, p = 0.006). Conclusions: Higher plasma AL concentrations in children at early school age with IF were modestly associated with lower IQ and visual memory scores. Plasma AL monitoring allows early detection of abnormal plasma concentration, minimization of AL in PN and potentially prevention of neurotoxicity in young children with IF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.